As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.
7 Analysts have issued a Cue Biopharma, Inc. forecast:
7 Analysts have issued a Cue Biopharma, Inc. forecast:
| Jun '25 | 
    +/-
   
    %
   | ||
| Revenue | 8.29 8.29 | 
      
        0%
      
      
        0%
      
 | |
| Gross Profit | - - | 
    -
 | |
| EBITDA | -39 -39 | 
      
        
        19%
      
      
        
        19%
      
 | |
| EBIT (Operating Income) EBIT | -39 -39 | 
      
        
        18%
      
      
        
        18%
      
 | |
| Net Profit | -39 -39 | 
      
        
        17%
      
      
        
        17%
      
 | |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.
| Head office | United States | 
| CEO | Daniel Passeri | 
| Employees | 41 | 
| Founded | 2014 | 
| Website | www.cuebiopharma.com | 
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


